Abstracts

INFECTIOUSNESS OF BREAKTHROUGH INFECTIONS AFTER VACCINATION AND NATURAL INFECTION

SARS-CoV-2 breakthrough infections in vaccinated individuals and in those who had a prior infection have been observed globally, but the transmission potential of these infections is unknown. Leveraging the national databases, effects of vaccination and of prior infection on SARS-CoV-2 infectiousness were investigated by comparing the RT-qPCR cycle threshold (Ct) values (inversely correlated with viral…

COVID-19 VACCINATION RATES IN A GLOBAL HIV COHORT

Little is known regarding global COVID-19 vaccination rates in people with HIV (PWH), a population with significant morbidity from COVID-19. The Randomized Trial to Prevent Vascular Events (REPRIEVE) is a global primary cardiovascular prevention trial among PWH (N=7770) with representation from >100 sites across twelve countries (Brazil, Botswana, Canada, Haiti, India, Peru, Spain, South Africa,…

THE IMPACT OF 3BNC117 AND ROMIDEPSIN TREATMENT AT ART INITIATION ON HIV-1 PERSISTENCE

Interventional reduction of the viral reservoir or induction of HIV-1 remission among individuals on long-term antiretroviral treatment (ART) have largely been unsuccessful. However, studies in non-human primates and mathematical modelling suggest that broadly neutralizing antibodies (bNAbs) or latency reversing agents administration at ART initiation may have a more profound effect on the establishment of HIV-1…

AZD5582 PLUS SIV mAbs TO REDUCE TISSUE RESERVOIRS IN ART-SUPPRESSED MACAQUES

The ‘shock-and-kill’ HIV cure strategy involves latency reversal and immune-mediated clearance of infected cells. Our prior work showed systemic SIV latency reversal using the SMACm / cIAP antagonist AZD5582. Here, we investigated AZD5582 in combination with a cocktail of 4 rhesus-derived SIV Env-specific monoclonal antibodies (mAbs) to reduce viral reservoirs in ART-suppressed rhesus macaques (RMs).…

HIV-1 REMISSION WITH CCR5∆32∆32 HAPLO-CORD TRANSPLANT IN A US WOMAN: IMPAACT P1107

Background: HIV-1 cure has been reported in two men with HIV-1 and malignancy following CCR5∆32 homozygousallogeneic adult stem cell transplantation. We report on a woman in ART-free HIV-1 remission for 14months following CCR5∆32 homozygous cord blood (CB) and CD34-selected haploidentical stem celltransplant (haplo-cord SCT) for acute myeloid leukemia (AML). Methods: IMPAACT P1107 is an observational…

MACROPHAGE ARTERIAL INFILTRATION RELATES TO PLAQUE TYPE AND IMMUNE ACTIVATION IN HIV

Persistent immune activation and downstream macrophage-specific arterial infiltration are thought to contribute to heightened atherosclerotic cardiovascular disease (ASCVD) risk among people with HIV (PWH) on ART. We applied a novel macrophage-specific imaging modality to investigate macrophage-specific infiltration among participants with vs without HIV in relation to atherosclerotic plaque and immune activation. Twenty PWH on ART…

TRENDS IN MYOCARDIAL INFARCTION RISK BY HIV STATUS IN 2 US HEALTHCARE SYSTEMS

With the potential adverse cardiovascular effects of newer antiretroviral therapy (ART), such as integrase inhibitors and weight gain and Tenofovir Alafenamide and elevated lipids, it is critical to continue monitoring trends in myocardial infarction (MI) rates by HIV status. Subjects included people with HIV (PWH) from two health system cohorts: Massachusetts General Hospital (Partners) and…